Skip to main content

Closed

IKT: Inhibikase Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-100.0% / yr

Operating margin0.0%

ROIC-33.2%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio30.14×

Inhibikase Therapeutics, Inc.

IKTNASDAQ·USD·Closed

Inhibikase Therapeutics, Inc.

IKTNASDAQ·USD·Closed

$2.18

−4.39%

$2.18

−$0.10 (4.39%)

52W Range

71thpctl

Volume

0.43×avg

Mkt Cap

287.83MUSD

P/E

-4.0TTM

Div Yield

–ann

52W Range

71thpctl

Volume

0.43×avg

Market Cap

287.83MUSD

P/E Ratio

-4.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings